Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage
- PMID: 365541
- DOI: 10.1007/BF00560460
Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage
Abstract
An ordinary and a sustained-release lithium carbonate preparation were administered acutely at equivalent dosage (1.80 g = 24.3 mmol) in a crossover fashion to manic patients. Serum lithium levels were determined by atomic absorption spectroscopy and pharmacokinetic parameters were calculated. Maximum mean serum levels of 1.13 mmol/l and 0.78 mmol/l were achieved at 6 h and 12 h respectively with the ordinary and sustained-release forms. The mean half-lives of absorption, redistribution and elimination were 0.78 h +/- 0.05 (SE), 5.06 h +/- 0.23, 26.8 h +/- 4.5 and 3.73 h +/- 0.37 (SE), 4.42 h +/- 0.28 and 25.6 h +/- 5.5 for the ordinary and sustained-release forms respectively. In healthy volunteers the ordinary preparation was completely absorbed but only 85% of the sustained-release form was absorbed in the manic subjects. Lithium ion distributed into two kinetic compartments and the final compartment appeared to correspond to total body water.
Similar articles
-
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.CNS Drugs. 2009;23(4):331-49. doi: 10.2165/00023210-200923040-00005. CNS Drugs. 2009. PMID: 19374461 Review.
-
Serum levels and pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients during chronic dosage.Int J Clin Pharmacol Ther Toxicol. 1986 May;24(5):257-61. Int J Clin Pharmacol Ther Toxicol. 1986. PMID: 3089950 Clinical Trial.
-
Pharmacokinetics of lithium preparations in patients.Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(1):63-70. doi: 10.1016/0278-5846(84)90136-2. Prog Neuropsychopharmacol Biol Psychiatry. 1984. PMID: 6427848 Clinical Trial.
-
Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations.Int J Clin Pharmacol Ther Toxicol. 1986 May;24(5):240-5. Int J Clin Pharmacol Ther Toxicol. 1986. PMID: 3089949
-
Mechanism of lithium carbonate in manic-depressive illness (a review).Dis Nerv Syst. 1971 May;32(5):335-41. Dis Nerv Syst. 1971. PMID: 4931497 Review. No abstract available.
Cited by
-
Formulation and in vitro-in vivo evaluation of sustained-release lithium carbonate tablets.Pharm Res. 1990 Apr;7(4):359-63. doi: 10.1023/a:1015863204732. Pharm Res. 1990. PMID: 2114020
-
Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.Eur J Clin Pharmacol. 2019 Apr;75(4):519-528. doi: 10.1007/s00228-018-2605-3. Epub 2018 Dec 15. Eur J Clin Pharmacol. 2019. PMID: 30554270
-
Distribution of lithium elimination rates in a selected population of psychiatric patients.Eur J Clin Pharmacol. 1982;21(4):351-4. doi: 10.1007/BF00637625. Eur J Clin Pharmacol. 1982. PMID: 7056282
-
The influence of assay variability on pharmacokinetic parameter estimation.J Pharmacokinet Biopharm. 1989 Oct;17(5):571-92. doi: 10.1007/BF01071350. J Pharmacokinet Biopharm. 1989. PMID: 2614686
-
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.CNS Drugs. 2009;23(4):331-49. doi: 10.2165/00023210-200923040-00005. CNS Drugs. 2009. PMID: 19374461 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical